mdlinx mdlinx
Print

Efficacy of cilostazol on uncontrolled coronary vasospastic angina: a pilot study
Cardiovascular Therapeutics, 04/24/2012

Yoo SY et al. – Cilostazol appears to be an effective therapy in VSA uncontrolled with conventional medical treatment. A further prospective, randomized, placebo–controlled study will be needed to validate this result.

Methods
  • This study was conducted in a prospective, multicenter, non–randomized manner.
  • The subject consisted of 21 patients (13 men, 57 ± 9 year–old) who were diagnosed with VSA and had at least two angina attacks during the past one week despite of conventional medications such as calcium channel blockers and/or nitrates.
  • They took Cilostazol 100 mg twice daily for two weeks in addition to the conventional medications.
  • The patients recorded the frequency of angina attack and wrote down the numeric rating scale of a ‘severity of angina attack’ while taking conventional medications and Cilostazol for two weeks, and also recorded an averaged scale or total number of event during the last week at the time of the assessment.
  • Using the Wilcoxon rank–sum test, authors compared the changes in the scores of frequency and severity of angina attack before and after adding Cilostazol to the conventional medications.

Results
  • After adding Cilostazol to the conventional medications, there were 78.9% relative reduction of the score of angina intensity and 73.5% of angina frequency (p < 0.001).
  • There were four patients (19%) who were forced to stop Cilostazol due to headache as an adverse event.

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close